Aligos Therapeutics (ALGS) vs aTyr Pharma (ATYR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aligos Therapeutics (ALGS) has outperformed aTyr Pharma (ATYR) over the past year, losing 46.5% versus a loss of 74.5%. Over five years, ATYR leads with a -97.1% price change compared with -98.7% for ALGS. Aligos Therapeutics is the larger company by market cap ($33.3 million vs $24.1 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALGS | ATYR |
|---|---|---|
| Share price | $5.34 | $0.2462 |
| Market cap | $33.35M | $24.15M |
| 1-day change | +0.56% | -3.56% |
| YTD return | -43.03% | -67.39% |
| 1-year return | -46.53% | -74.47% |
| 5-year return | -98.66% | -97.07% |
| EPS (TTM) | $-7.41 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.69 | $1.12 |
| 52-week low | $3.98 | $0.246 |
| Distance from 52-week high | -60.99% | -78.02% |
| Analyst consensus | none | buy |
| Avg. price target upside | +880.90% | +1061.66% |
| Average volume | 88.98K | 3.24M |
| Shares outstanding | 5.44M | 98.09M |
| Employees | 82 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALGS has outperformed ATYR by 27.9 percentage points over the past year.
About Aligos Therapeutics
ALGS stock →Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees
About aTyr Pharma
ATYR stock →aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 58 employees
ALGS vs ATYR FAQ
Which is bigger, Aligos Therapeutics or aTyr Pharma?
Aligos Therapeutics (ALGS) is larger, with a market capitalization of $33.35M compared with $24.15M for aTyr Pharma (ATYR).
Which stock has performed better over the past year, ALGS or ATYR?
ALGS returned -46.53% over the past 12 months, compared with -74.47% for ATYR (price return, excluding dividends). Past performance does not predict future results.
Are Aligos Therapeutics and aTyr Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.